Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 2/20 | 0.35 |
| ▸ | RARB | P10826 | 2/20 | 0.35 |
| ▸ | RARG | P13631 | 2/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.32 |
| ▸ | RXRA | P19793 | 7/20 | 0.30 |
| ▸ | RXRB | P28702 | 5/20 | 0.30 |
| ▸ | RXRG | P48443 | 4/20 | 0.30 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4669326 | 0.86 | RARA (0.36) | RARARARBRARGCYP26B1RXRA | |
| SCHEMBL4781418 | 0.86 | RARA (0.36) | RARARARBRARGCYP26B1RXRA | |
| SCHEMBL14159837 | 0.86 | RARA (0.30) | RARARARBRARG | |
| SCHEMBL4668099 | 0.83 | RXRA (0.37) | RARARARBRARGPTGS1PTGS2 | |
| SCHEMBL14018628 | 0.82 | RARA (0.34) | RARARARBRARGCYP26B1RXRA | |
| SCHEMBL11122818 | 0.81 | RARB (0.41) | RARARARBRARGCYP26B1RXRA | |
| SCHEMBL4668140 | 0.80 | PTGS2 (0.45) | RARARARBRARGPTGS1PTGS2 | |
| SCHEMBL14159883 | 0.76 | RARB (0.68) | RARARARBRARGRXRARXRB | |
| SCHEMBL14018552 | 0.74 | RARB (0.52) | RARARARBRARGPTGS1PTGS2 | |
| SCHEMBL8807547 | 0.73 | RXRA (0.44) | RARARARBRARGRXRARXRB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1324970-B1 | RETINOIDS FOR THE TREATMENT OF EMPHYSEMA | HOFFMANN LA ROCHE (CH) | 2008-11-05 | — | — | EP | disclosed |
| EP-1935869-A1 | Retinoids for the treatment of emphysema | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| EP-1935869-A1 | Retinoids for the treatment of emphysema | F. HOFFMANN-LA ROCHE AG (CH) | 2008-06-25 | — | — | EP | disclosed |
| US-6777418-B2 | FOR TREATING OR PREVENTING EMPHYSEMA, CANCER AND DERMATOLOGICAL DISORDERS | SYNTEX (U.S.A.) LLC | 2004-08-17 | — | — | US | disclosed |
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | SYNTEX (U.S.A.) LLC | 2002-06-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020082265-A1 | For treating or preventing emphysema, cancer and dermatological disorders | RXRA, RXRG, RXRB | RARA 5/4885RARB 6/4885RARG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.